ARTICLE | Clinical News
Kezar reports Phase Ia data for autoimmune disease candidate KZR-616
July 28, 2017 5:51 PM UTC
Kezar Life Sciences Inc. (South San Francisco, Calif.) reported data from a Phase Ia trial in 82 healthy volunteers showing that single and multiple ascending doses of once-weekly subcutaneous KZR-616 were well tolerated. Additional data will be presented at the American College of Rheumatology and the Association of Rheumatology Health Professionals meeting in San Diego in November...
BCIQ Company Profiles